Design Therapeutics Q1 Earnings Call Highlights

Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich’s ataxia (FA), emphasizing ...
Precision Medicine Online

Solid Biosciences Testing Dual Delivery Gene Therapy in First-in-Human Friedreich's Ataxia Trial

The firm will deliver SGT-212 to patients' brains and intravenously to try to restore frataxin levels and diminish ...
Seeking Alpha

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and ...

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dr. Ronald Crystal is a founder, chief scientific advisor, consultant, equity holder and board observer of Lexeo Therapeutics and is an inventor on intellectual property assigned to Weill Cornell ...
Forbes

Gene Editing Or Gene Silencing: The Therapies Poised To Transform Medicine

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...